How will the existing vaccine work against the new variant Expert replied

Pune . Director of All India Institute of Medical Sciences (AIIMS), Delhi Dr. Randeep Guleria (AIIMS Director Dr Randeep Guleria) It has said that the anti-Corona vaccine can be ‘modified’ to provide protection against new forms of the virus. Guleria’s comment is a new form of Kovid-19 Omicron variant In view of the concerns regarding Dr. Guleria said here on Sunday, ‘Although it is a new form of COVID-19, the glimmer of hope is that it seems to be a mild disease and we should have protection as far as vaccine is concerned. . I think it is important to remember that vaccines can be modified.

Dr. Randeep Guleria, Director, AIIMS Delhi Said, ‘We will have second generation vaccines. This is something that we need to keep in mind. The existing vaccines are effective, but with the new form, their immunity will decrease, although the vaccines can be modified. He was organized by the Association of Physicians of India here in Maharashtra, Dr. V.S. was speaking at Prayag Memorial Oration 2021.

read this also : Omicron Variant: What will be the effect of booster dose on Omicron? How effective will Kovovax be?

read this also : Omicron Alert: Rajasthan is ready to face every situation, know all the updates related to Corona

Dr. Guleria said, every year World Health Organization (WHO) A new vaccine (for common diseases) is made based on surveillance data provided by The Omicron form of the corona virus was first detected in South Africa on 24 November, in India, its first two cases were reported in Karnataka on 2 December. Till Sunday, 153 cases of Omicron had been reported in India.

List of emergency uses for Kovax released: WHO

On December 17, 2021, the World Health Organization released a list of emergency uses for Kovax. WHO It says that this is an important step to promote the vaccine in low-income countries. The organization says that Kovovax was evaluated by the Drug Controller General of India based on a review of data from its efficacy, quality, safety and risk management plan. The World Health Organization’s expert group believes that the benefits of the vaccine far outweigh its risks and that it can be used worldwide. Reports suggest that the Expert Committee (SEC) of India’s Central Drugs Standard Control Organization (CDSCO) had sought more data related to Kovavax from SII so that permission could be obtained from the Drug Controller General for its emergency use.

Tags: AIIMS Director Dr Randeep Guleria, Anti-Corona vaccine, Omicron variant


(This is an auto-generated article from syndicated news feed. TEAM BEPINKU.COM may not have modified or edited the article).

About the Author: TEAM BEPINKU.COM

We share trending news and latest information on Business, Technology, Entertainment, Politics, Sports, Automobiles, Education, Jobs, Health, Lifestyle, Travel and more. That's our work. We are a team led by Mahammad Sakil Ansari.

You May Also Like